List view / Grid view
Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president,…
7 May 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company...
Bristol-Myers Squibb Company announced that the U.S. Food and Drug…
24 February 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted its investigational DCV Dual Regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection...
Bristol-Myers Squibb application supports use of daclatasvir in combination with…
8 January 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4...
"We are pleased to be one step closer to bringing…
2 November 2013 | By Bristol-Myers Squibb Company
"We are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV..."
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the…
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...
Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed…
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have…
1 October 2013 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013...
Results from the Phase 3 randomized, double-blind clinical trial (Study…
12 September 2013 | By Bristol-Myers Squibb Company
Results from the Phase 3 randomized, double-blind clinical trial (Study 043)...
SAVOR provides information on cardiovascular safety for Onglyza in the…
2 September 2013 | By AstraZeneca
SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments...
Results from Study 004...
2 June 2013 | By Bristol-Myers Squibb Company
Results from Study 004...
The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)...
3 May 2013 | By Bristol-Myers Squibb Company
The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)...
Results from Phase 2 open-label study...
9 December 2012 | By Bristol-Myers Squibb Company
Results from Phase 2 open-label study...
Phase III development anticipated to begin in 2014...
12 November 2012 | By Bristol-Myers Squibb Company
Phase III development anticipated to begin in 2014...
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer announced a…
1 November 2012 | By Bristol-Myers Squibb Company
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer announced a clinical collaboration agreement...
Results of the phase III BRISK-FL clinical trial...
19 July 2012 | By Bristol-Myers Squibb Company
Results of the phase III BRISK-FL clinical trial...
